Frequency of frontotemporal dementia-related gene variants in Turkey

ARTAN S., ERZURUMLUOĞLU GÖKALP E., Samanci B., Adapinar D. O., Bas H., Tepgec F., ...Daha Fazla

NEUROBIOLOGY OF AGING, cilt.106, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 106
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.neurobiolaging.2021.05.007
  • Dergi Adı: NEUROBIOLOGY OF AGING
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Anahtar Kelimeler: Frontotemporal dementia, Next generation sequencing, Turkey, AMYOTROPHIC-LATERAL-SCLEROSIS, DNA-BINDING PROTEIN, LOBAR DEGENERATION, PROGRANULIN MUTATIONS, HEXANUCLEOTIDE REPEAT, PAGET-DISEASE, MAPT GENE, TAU, TDP-43, C9ORF72
  • İstanbul Üniversitesi Adresli: Evet

Özet

Just as its clinical heterogeneity, genetic basis of Frontotemporal dementia (FTD) is also diverse and multiple molecular pathways are thought to be involved in disease pathogenesis. In the present study, FTD-related genes were evaluated in a Turkish cohort of 175 index FTD patients with a gene panel including GRN, MAPT, TARDBP, FUS, CHMP2B and VCP genes. Potential genetic associations were prospected in 16 patients (9.1%); five variants (p.(Gly35Glufs) and p.(Cys253Ter) in GRN; p.(Arg95Cys) in VCP; p.(Met405Val) in TARDBP and p.(Pro636Leu) in MAPT) were classified as pathogenic (P) or likely pathogenic (LP), in four familial and one sporadic patients. Three novel variants in MAPT, CHMP2B and FUS were also identified in familial cases. The most common pathogenic variants were observed in the GRN gene with a frequency of 1.14% (2/175) and this rate was 4.57% (8/175), including variants of uncertain significance (VUS). In this study with the largest cohort of Turkish FTD patients, GRN and MAPT variants were identified as the most common genetic associations; and rare causes like VCP, TARDBP, CHMP2B and FUS variants are recommended to be considered in patients with compatible clinical findings. (C) 2021 Elsevier Inc. All rights reserved.